Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Video Interview: Grünenthal Reveals Plans To Maintain Robust Growth Following Strong 2015

This article was originally published in Scrip

Executive Summary

While other pharma majors have struggled against a number of headwinds, Grünenthal GmbH saw a solid year of growth in 2015 with anticipated revenues of some €1.2bn. Speaking to Informa Pharma Insight's global director of content Mike Ward at the recent Biotech Showcase, Grünenthal's CSO, Dr. Klaus Langner, explains what underpinned this performance as well as discussing the company's plans to expand beyond its core strength in pain management to niche therapeutic fields. Plans include increasing investment in R&D, establishing new partnerships and licensing agreements to bolster the pipeline and existing product portfolios to access assets identified by a four-person innovative medicines unit.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts